While only three of the breast cancers in this study are HER2+ (as classified by clinical pathology immunohistochemistry (IHC) stain; Table S1 in Additional file 1), ERRB2 transcript levels were elevated in several of the early neoplasia samples relative to normal and suggests a possible function for HER2 at this early stage. Here, ERBB2 is linked to breast cancer.